Key result
Serum paraoxonase-1 levels were significantly lower in patients with chronic kidney disease compared to healthy controls and strongly correlated with impaired aortic functions.
Why the study?
Are serum paraoxonase-1 levels correlated with impaired aortic functions in patients with chronic kidney disease?
Case-Control (n=91)
Are serum paraoxonase-1 levels correlated with impaired aortic functions in patients with chronic kidney disease?
Absolute Event Rate: 104.26% vs 203.11%
p-value: p=< 0.001
Serum paraoxonase-1 levels are significantly reduced in patients with chronic kidney disease and strongly correlate with increased aortic stiffness, suggesting a mechanistic link between oxidative stress and premature vascular aging in this population.
Reduced paraoxonase-1 associates with aortic impairment in CKD; leaves open causal and therapeutic implications.
BACKGROUND: The correlation between aortic functions and paraoxonase levels has been previously demonstrated by several earlier studies. In this study, we aimed to investigate the correlation between serum paraoxonase levels and aortic functions among patients with chronic kidney disease. METHODS: Our study enrolled 46 chronic kidney disease patients and 45 healthy controls. From these patients, serum cholesterol, creatinine, hemoglobin, and paraoxonase-1 levels were analyzed. RESULTS: Paraoxonase-1 levels were significantly lower in patients with chronic kidney disease compared to the controls (p < 0.001). Additionally, the extent of aortic stiffness index (%) was significantly higher in chronic kidney disease patients, but aortic strain and aortic distensibility were significantly higher in healthy controls (p < 0.001, p < 0.001, and p < 0.001, respectively). We further found that paraoxonase-1 levels were correlated with aortic stiffness index, aortic strain, and aortic distensibility (p < 0.001, p < 0.001, and p < 0.001, respectively). CONCLUSIONS: Our study demonstrated that serum paraoxonase-1 levels were significantly correlated with impaired aortic functions. The results of this study highlight the impact of serum paraoxonase-1 activity on atherosclerosis and cardiovascular adverse events.
No takes yet. Share an insight, caveat, or question.
Efe et al. (2016) conducted a case-control in Chronic kidney disease (n=91). Chronic kidney disease vs. Healthy controls was evaluated on Serum paraoxonase-1 (PON-1) levels (U/L) (p=< 0.001). Serum paraoxonase-1 levels were significantly lower in patients with chronic kidney disease compared to healthy controls and strongly correlated with impaired aortic functions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: